Cecilia Pessoa Gingerich

Patients treated with faricimab every 16 weeks had a mean improvement of 11.4 letters from baseline, compared to 9.6 letters in those treated with ranibizumab every 4 weeks.

The phase 2 FILLY trial found that APL-2 injections both monthly and every other month slowed lesion growth compared to sham.

In patients with neovascular AMD, 24% receiving brolucizumab had intra-retinal fluid and/or sub-retinal fluid compared to 37% of aflibercept-treated patients in the HAWK trial.

An anti-PIGF, a plasma kallikrein inhibitor, and a pan RGD integrin antagonist are some of the investigational treatments in the pipeline for diabetic retinopathy and diabetic macular edema.

David Brown, a retina specialist discusses how retina and diabetes specialists can coordinate care and education for their patients as well as the outlook for AMD/DME research.

In a phase 2 study, a long-acting, implantable delivery system for ranibizumab allowed patients with wet age-related macular degeneration to go up to 15 months before requiring a refill.

Along with sports cardiology and pediatric cardiology, Robert Battle specializes in treating patients with hypertrophic cardiomyopathy, the most common genetic cardiovascular disorder.

The SynchroMed II myPTM Personal Therapy Manager allows patients with chronic pain to manage unpredictable pain by delivering on-demand doses within limits set by their provider.

Data from the SELECT-MONOTHERAPY trial in patients with rheumatoid arthritis show that upadacitinib improved outcomes in pain, physical function, health-related quality of life, and morning stiffness.

The updated label includes safety and efficacy data about the use of rituximab as follow-up treatment for patients with granulomatosis with polyangiitis and microscopic polyangiitis.

Yutiq, a fluocinolone acetonide intravitreal implant, is indicated for the treatment of chronic non-infectious uveitis that affects the posterior segment of the eye.

Data from 2 phase 3 studies of secukinumab (Cosentyx) in patients with psoriatic arthritis and ankylosing spondylitis will be presented at an upcoming meeting.

First approved in 2015, the levonorgestrel-releasing Liletta IUD is now approved for contraceptive use for up to 5 years.

The ID CORE XT is the second molecular assay approved for use in transfusion medicine and the first to report results as genotypes.

Rivaroxaban (Xarelto) is now indicated to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease.

Previously approved in 2015, Stiolto Respimat Inhalation Spray is now indicated for the treatment of COPD including chronic bronchitis and emphysema.

The IMPLANT 2 trial of nolasiban showed a significant increase in the rates of ultrasound-confirmed pregnancy at 10 weeks as well as live births.

In a head-to-head trial, fingolimod (Gilenya) significantly reduced relapses over the course of one year compared to glatiramer acetate (Copaxone), in patients with relapsing-remitting multiple sclerosis.

New data from open-label extension studies of ocrelizumab show that patients with relapsing multiple sclerosis and primary progressive multiple sclerosis had better outcomes with earlier treatment.

The application was based on data from the EXPAND phase 3 trial of siponimod in adults with secondary progressive multiple sclerosis.

Investigators analyzed data from PrEP-eligible patients at the New York City Health + Hospital/Bellevue which showed that women and minority patients were less likely to be prescribed PrEP for HIV prevention.

Race and sex can play a role in the annual BMI gain for patients with HIV who are receiving certain antiretroviral therapy combinations.

An intervention of scheduling an appointment and contacting the patient successfully increased re-engagement among patients with HIV who had not had a primary care visit in the previous 6 months.

An interview-based qualitative study found that minority residents face extra burdens during training due to racial/ethnic bias and microaggressions.

Galcanezumab will be available as a monthly 120 mg injection in pen and syringe forms for the prevention of migraine in adults.

The FDA has approved a 0.15mg dosage of Symjepi, an epinephrine injection, for the emergency treatment of serious allergic reactions in children.

The FDA recognized the potential of proCase, which is being developed to treat blood clots and does not increase the risk of bleeding.

The Eluvia stent system was approved based on data from the IMPERIAL non-inferiority trial, which compared Eluvia to Zilver PTX.

The capsules of icosapent ethyl, which is derived from fish, showed a 25% relative risk reduction compared to placebo.

Lucia Novak discusses the importance of testing for cardiovascular outcomes of diabetes treatments and compares the cardiovascular effects of several diabetes drugs.